Acta Scientific Pharmacology

Case Report Volume 2 Issue 9

A Case Report of Iloperidone-induced Sleep-related Eating Disorder

Hani Raoul Khouzam*

Department of Psychiatry, Sacramento VA Medical Center and UC Davis Health, Sacramento, California, USA

*Corresponding Author: Hani Raoul Khouzam, MD;MPH. Staff Psychiatrist Department of Psychiatry, Sacramento VA Medical Center Clinical professor of Psychiatry and Medicine, UC Davis Health, Sacramento, California USA.

Received: August 21, 2021; Published: August 30, 2021


  Sleep-related eating disorder is a Non-Rapid Eye Movement Sleep Arousal Disorders characterized by recurrent episodes of nocturnal eating or drinking after an arousal from the Non-Rapid Eye Movement (NREM) sleep stage. Several medications, including atypical antipsychotics, have been reported to induce sleep-related eating disorder. This case report illustrates the development of sleep -related eating disorder during treatment with the atypical antipsychotic Iloperidone. It also reviews Iloperidone core mechanisms of action of and propose a possible link between its effects on 5-hydroxytryptamine-2A and 2C (5-HT2A) and (5-HT2C) neuroreceptors and the development of Sleep-related eating disorder.

Keywords: Schizophrenia; Sleep-related Eating Disorder; Atypical Antipsychotics; Iloperidone; Treatment


  1. American Psychiatric Association. The Diagnostic and Statistical Manual of Mental Disorders: DSM-5. Washington, DC: American Psychiatric Association (2013).
  2. Chiaro G., et al. “Treatment of sleep-related eating disorder”. Current Treatment Options in Neurology 8 (2015): 361.
  3. Inoue Y. “Sleep-related eating disorder and its associated conditions”. Psychiatry Clinical Neuroscience6 (2015): 309-320.
  4. American Academy of Sleep Medicine. The International Classification of Sleep Disorders: diagnostic and coding manual. 2nd ed. Westchester, IL: American Academy of Sleep Medicine (2005).
  5. Schenck CH., et al. “Sleep-related eating disorders: polysomnographic correlates of a heterogeneous syndrome distinct from daytime eating disorders”. Sleep 14 (1991): 419-431.
  6. Schenck C., et al. “Additional categories of sleep-related eating disorders and the status of treatment”. Sleep 16 (1993): 457-466.
  7. Morgenthaler TI and Silber MH. “Amnestic sleep-related eating disorder associated with zolpidem”. Sleep Medicine 3 (2002): 323-327.
  8. Yun CH and Ji KH. “Zolpidem-induced sleep-related eating disorder”. Journal of Neurological Science 288 (2010): 200-201.
  9. Paquet V., et al. “Sleep-related eating disorder induced by olanzapine”. The Journal of Clinical Psychiatry 63 (2002): 597.
  10. Lu M and Shen W. “Sleep-related eating disorder induced by risperidone”. The Journal of Clinical Psychiatry 65 (2004): 273-274.
  11. Heathman JC and Neal DW. “Sleep related eating disorder associated with quetiapine”. The Journal of Clinical Psychopharmacology 34 (2014): 658-660.
  12. Kobayashi N and Takano M. “Aripiprazole-induced sleep-related eating disorder: a case report”. Journal of Medical Case Reports 1 (2018): 91.
  13. McGrath J., et al. “Schizophrenia: a concise overview of incidence, prevalence, and mortality”. Epidemiology Review 30 (2008): 67-76.
  14. Potkin SG., et al. “The neurobiology of treatment-resistant schizophrenia: paths to antipsychotic resistance and a roadmap for future research”. NPJ Schizophrenia1 (2020): 1.
  15. Weiden PJ. Iloperidone for the treatment of schizophrenia: an updated clinical review”. Clinical Schizophrenia and Related Psychoses 1 (2012): 34-44.
  16. Howes O D., et al. “Treatment-resistant schizophrenia: treatment response and resistance in psychosis (TRRIP) working group consensus guidelines on diagnosis and terminology”. American Journal of Psychiatry3 (2017): 216-229.
  17. Bishop JR and Bishop DL. “Iloperidone for the treatment of schizophrenia”. Drugs Today (Barc)8 (2010): 567-579.
  18. Crabtree BL and Montgomery J. “Iloperidone for the management of adults with schizophrenia”. Clinical Therapy3 (2011): 330-345.
  19. Musil R., et al. “Weight gain and antipsychotics: a drug safety review”. Expert Opinion on Drug Safety 1 (2015): 73-96.
  20. Seeman M. “Sleepwalking, a possible side effect of antipsychotic medication”. Psychiatric Quality 82 (2011): 59-67.
  21. Ichikawa J., et al. “Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: role of 5-HT1A receptor agonism”. Brain Research 956 (2002): 349-357.
  22. Puig MV., et al. “Serotonin modulates fast-spiking interneuron and synchronous activity in the rat prefrontal cortex through 5-HT1A and 5-HT2A receptors”. Journal of Neuroscience 30 (2010): 2211-2222.
  23. Heisler LK., et al. “Serotonin 5-HT (2C) receptors regulate anxiety-like behavior”. Genes, Brain and Behavior 6 (2007): 491-496.
  24. Nonogaki K., et al. “Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene”. Nature Medicine 4 (1998): 1152-1156.
  25. Uwaifo GI. “Obesity-associated hypertension. Contemporary Endocrinology Endocrine Hypertension”. Edited by: Koch CA, Chrousos GP. New York: Springer (2013): 251-288.


Citation: Hani Raoul Khouzam. “A Case Report of Iloperidone-induced Sleep-related Eating Disorder".Acta Scientific Pharmacology 2.9 (2021): 28-32.


Copyright: © 2020 Hani Raoul Khouzam. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Acceptance rate36%
Acceptance to publication20-30 days

Indexed In

News and Events

  • Certification for Review
    Acta Scientific certifies the Editors/reviewers for their review done towards the assigned articles of the respective journals.
  • Submission Timeline for Upcoming Issue
    The last date for submission of articles for regular Issues is June 25, 2024.
  • Publication Certificate
    Authors will be issued a "Publication Certificate" as a mark of appreciation for publishing their work.
  • Best Article of the Issue
    The Editors will elect one Best Article after each issue release. The authors of this article will be provided with a certificate of "Best Article of the Issue"
  • Welcoming Article Submission
    Acta Scientific delightfully welcomes active researchers for submission of articles towards the upcoming issue of respective journals.

Contact US